1. Home
  2. VITL vs DSGN Comparison

VITL vs DSGN Comparison

Compare VITL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$12.66

Market Cap

588.6M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

BUY

Current Price

$11.17

Market Cap

579.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
VITL
DSGN
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
588.6M
579.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
VITL
DSGN
Price
$12.66
$11.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
$37.90
$15.25
AVG Volume (30 Days)
2.6M
271.2K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
N/A
EPS
1.44
N/A
Revenue
$759,444,000.00
N/A
Revenue This Year
$21.13
N/A
Revenue Next Year
$18.17
N/A
P/E Ratio
$8.74
N/A
Revenue Growth
25.26
N/A
52 Week Low
$12.35
$2.62
52 Week High
$53.13
$11.30

Technical Indicators

Market Signals
Indicator
VITL
DSGN
Relative Strength Index (RSI) 20.37 62.58
Support Level N/A $9.71
Resistance Level $33.73 N/A
Average True Range (ATR) 0.90 0.56
MACD 0.19 0.07
Stochastic Oscillator 4.76 95.07

Price Performance

Historical Comparison
VITL
DSGN

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: